clinical trial · NCT07129252
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine NeoplasmCRN09682
brief summary
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
started
Nov 26, 2025
primary completion
Aug 1, 2027
completion
Aug 1, 2029
last updated
Mar 10, 2026
official title
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol